Ranbaxy teeters on Caraco-ism

The recent FDA warning letter to Ohm Laboratories, in which the regulator calls "inadequate" the company's corrective measures to fix GMP violations, has left the company in a precarious position. Following three responses to the FDA after a detailed inspection of Ohm's Gloversville, NY, facility (as reported earlier) the company now must redouble its efforts to restore its credentials as a U.S. drug supplier. Ohm is the U.S. arm of Indian generics maker Ranbaxy, now owned by Japan's Daiichi Sankyo.

"It is indeed a poor reflection on how the company is dealing with an extremely serious condition," writes pharma columnist "Pillman," who is identified in Mumbai-based DNA (Daily News & Analysis) as a global pharma executive. Pillman speculates that if the FDA needs to take additional action, it is likely to surpass a strongly worded letter.

The columnist acknowledges that Ranbaxy has hired manufacturing consultancy PRTM to help get itself on track. So that places it a step ahead of Caraco--the U.S. arm of India-based generics maker Sun Pharmaceutical Industries--which starred as the 2009 poster child for a tougher FDA. Caraco did not hire a consultant until it was court-ordered to do so, following seizure by U.S. marshals of products and inventory from facilities in Detroit.

- here's the article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.